Myeloid Antigen, CD13, CD14, and/or CD33 Expression Is Restricted to Certain Lymphoid Neoplasms

Abstract

The authors examined the expression of myeloid antigens (MyAg): CDMb, CDI3, CD14, CD15, and CD33 in 249 adults with lymphoid neoplasms using flow cytometric analysis. In this study, acute leukemia that was myeloperoxidase negative by light microscopy and had at least one lymphoid antigen was defined as acute lymphoblastic leukemia (ALL). The patients were classified as follows: 6 with unclassified ALL, 35 early B precursor ALL, 32 T-ALL, 25 B-cell chronic lymphocytic leukemia (B-CLL) and its variants, 24 B-cell non-Hodgkin's lymphoma (B-NHL), 7 plasma cell disorders, 8 T-CLL, 2 adult T-cell leukemia, and 10 T-NHL. CD1 lb and CD15 were present in a wide range of lymphoid disorders irrespective of B/T lineage and maturity. Unclassified ALL and phenotypically immature ALL frequently expressed CD13Immunophenotypic investigation using comprehensive panels of monoclonal antibodies (MoAbs) to various hematopoietic differentiation antigens have provided unique information for the studies of hematologic neoplasms. 1 ' 2 In a variety of hematologic disorders, investigators have discovered that a substantial proportion of the cases possess characteristics of more than one hematopoietic cell lineage. "6 Among these studies, it is intriguing that many myeloid antigens (MyAgs) can be ex- 10 unlike the range of the expression of lymphoid antigen (LyAg) in acute myelocytic leukemia (AML).6 " However, little is known about the distribution pattern of MyAg expression as to whether it is broadly scattered in lymphoid malignancies or concentrated in certain neoplasms. This issue is fundamentally important to understand the biologic and clinical importance of MyAg in lymphoid neoplasms.In the present study, we investigated the expression of MyAg such as CD1 lb, CD 13, CD 14, CD 15, and CD33 in a whole spectrum of lymphoid malignancies to clarify the distribution characteristics of MyAg expression in relation to the presence of stem cell marker CD34 and chromosomal abnormalities. Our results show that the expression of certain MyAgs such as CD 13, CD 14, and/ or CD33 is relatively restricted to two major groups of lymphoid neoplasms, namely undifferentiated ALL and mature B-cell malignancies. MATERIALS AND METHODS PatientsCell samples were taken from 249 Japanese adult patients (older than 15 years) with lymphoid neoplasms.

Flowcytometric comparative analysis in acute leukemias between Indian and proposed minimal screening panel

“…Studies have also shown that CD13 and CD33 positivity is commonly seen in 6-16% and 3-10% of ALL cases respectively [36][37][38] and they are frequently associated with t(9;22). 39,40 In our study, we found Philadelphia chromosome t According to available literature, CD7 expression is seen in 20% of AML, CD19 in 5% of AML, CD10 in 3% of AML, and sCD3 in 1% of AML. [41][42][43] This was in close concordance with our study results.…”

Flow cytometric immunophenotyping for hematologic neoplasms

“…Although it has been reported infrequently in many different subtypes of mature lymphoid neoplasm, aberrant myeloid antigen expression is perhaps most often found in lymphoplasmacytic lymphoma (LPL). 16 Notably, CD5 expression on B cells is often referred to as an aberrant phenotype, but small populations of normal, mature CD5 ϩ B cells exist. Nonneoplastic CD5 ϩ B cells are found most often in the peripheral blood, but may also be seen in lymph node specimens, especially in patients with autoimmune disease.…”

New Aspects of Siglec Binding Specificities, Including the Significance of Fucosylation and of the Sialyl-Tn Epitope

“…However, this was concluded only from experiments using resialylated red blood cells (11). Siglec-3 is found on myelomonocytic progenitor cells, monocytes, and macrophages and is a marker for acute myeloid leukemias (31)(32)(33), but no specific function has yet been ascribed to it. Siglec-4a (myelin-associated glycoprotein) is found only in the nervous system and is involved in maintenance of myelin sheath integrity (34,35).…”